secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tectonic Therapeutic, Inc. (TECX)
CIK:        0001681087
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001193125-25-269573
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tectonic Q3 net loss $19M; positive TX45 Phase 1b data in PH-HFrEF
------------------------------------------------------------------

- Net loss of $19.0M in Q3 2025 vs $17.7M in Q3 2024; R&D expenses $16.9M.
- Cash and equivalents $268.4M as of Sept 30, 2025; runway into Q4 2028.
- TX45 Part B: 29.2% reduction in PCWP, 17.3% improvement in cardiac output in PH-HFrEF.
- TX45 APEX Phase 2 in PH-HFpEF over 50% enrolled; topline results expected in 2026.
- TX2100 Phase 1 for HHT to start Q1 2026; TX45 PH-ILD Phase 2 planned in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1681087/000119312525269573/0001193125-25-269573-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1681087/000119312525269573/tecx-20251106.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-269573

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer